المؤلفون: Monk, Bradley J, Poveda, Andrés, Vergote, Ignace, Raspagliesi, Francesco, Fujiwara, Keiichi, Bae, Duk-Soo, Oaknin, Ana, Ray-Coquard, Isabelle, Provencher, Diane M, Karlan, Beth Y, Lhommé, Catherine, Richardson, Gary, Rincón, Dolores Gallardo, Coleman, Robert L, Marth, Christian, Brize, Arija, Fabbro, Michel, Redondo, Andrés, Bamias, Aristotelis, Ma, Haijun, Vogl, Florian D, Bach, Bruce A, Oza, Amit M

المصدر: Gynecologic Oncology. 143(1)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Ovarian Cancer, Clinical Research, Cancer, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Ascites, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Paclitaxel, Recombinant Fusion Proteins, Trebananib, TRINOVA-1, Recurrent epithelial ovarian cancer, Overall survival, Time to second disease progression, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine

URL الوصول: https://escholarship.org/uc/item/3rz4f3ff

المؤلفون: Simon Chowdhury, Paul Mainwaring, Liangcai Zhang, Suneel Mundle, Eneida Pollozi, Alexander Gray, Mark Wildgust

المصدر: Frontiers in Oncology, Vol 10 (2020)

مصطلحات موضوعية: PFS2, OS, second disease progression, surrogate clinical endpoint, time to progression on second therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fonc.2020.01349/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/1239882d59684e8893bcd1c066c55dfb

المؤلفون: Suneel Mundle, Paul N. Mainwaring, Liangcai Zhang, Mark Wildgust, Eneida Pollozi, Alexander Gray, Simon Chowdhury

المصدر: Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Randomization, Correlation coefficient, PFS2, lcsh:RC254-282, law.invention, Correlation, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Progression-free survival, time to progression on second therapy, surrogate clinical endpoint, business.industry, OS, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Random effects model, second disease progression, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, Meta-analysis, Systematic Review, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01fa306d105f93c6e9bf7640fe54d2c0
https://doi.org/10.3389/fonc.2020.01349

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Diane Provencher, Andres Poveda, Michel Fabbro, Isabelle Ray-Coquard, Ignace Vergote, Duk-Soo Bae, Bradley J. Monk, Dolores Gallardo Rincón, Andrés Redondo, Bruce A. Bach, Francesco Raspagliesi, Haijun Ma, Aristotelis Bamias, Beth Y. Karlan, Christian Marth, Florian D. Vogl, Gary Richardson, Ana Oaknin, Amit M. Oza, Robert L. Coleman, Keiichi Fujiwara, Arija Brize, Catherine Lhommé

المصدر: Monk, BJ; Poveda, A; Vergote, I; Raspagliesi, F; Fujiwara, K; Bae, D-S; et al.(2016). Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. GYNECOLOGIC ONCOLOGY, 143(1), 27-34. doi: 10.1016/j.ygyno.2016.07.112. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3rz4f3ff
Gynecologic oncology, vol 143, iss 1

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_treatment, Phases of clinical research, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Overall survival, Aged, 80 and over, Ovarian Neoplasms, education.field_of_study, Obstetrics and Gynecology, Ascites, Middle Aged, Local, 030220 oncology & carcinogenesis, Female, Trebananib, medicine.drug, Adult, medicine.medical_specialty, Bevacizumab, Paclitaxel, Recombinant Fusion Proteins, Time to second disease progression, Population, Oncology and Carcinogenesis, Subgroup analysis, and over, Recurrent epithelial ovarian cancer, Placebo, Disease-Free Survival, Paediatrics and Reproductive Medicine, 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Humans, Progression-free survival, Oncology & Carcinogenesis, Adverse effect, education, Aged, Gynecology, Chemotherapy, business.industry, 030104 developmental biology, Neoplasm Recurrence, TRINOVA-1, Neoplasm Recurrence, Local, business

وصف الملف: application/pdf; Print-Electronic

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbde7fbacb1d4616a2fc8a859e57e7c7
http://www.escholarship.org/uc/item/3rz4f3ff